Immunogenetic and molecular biomarkers in COVID-19 and hepatitis C virus infection: Evaluating the diagnostic potential of HLA (rs1131500), IGF-2, and I-FABP

doi:10.4254/wjh.v18.i3.112850

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

(37)

(28)

(0)

(14)

(569)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Hepatol. Mar 27, 2026; 18(3): 112850
Published online Mar 27, 2026. doi: 10.4254/wjh.v18.i3.112850

Full Size Figure Download Figure

Figure 6 Distribution of CC, CT, and TT genotypes across the four study groups (hepatitis C virus-coronavirus disease 2019, coronavirus disease 2019, hepatitis C virus, and Control). This distribution suggests potential differences in genotype association with hepatitis C virus, coronavirus disease 2019, and co-infection. HCV: Hepatitis C virus; COVID-19: Coronavirus disease 2019.

Citation: Mohamed AA, Abdel-Hamid RM, Amin A, A Gawad EAH, Saed SM, Gaber DA, Ezz Al Arab M, El-Agawy W, AbuRahma MZA, Elosaily HH, Shaaban EE, Ismail SA, Sakr AA. Immunogenetic and molecular biomarkers in COVID-19 and hepatitis C virus infection: Evaluating the diagnostic potential of HLA (rs1131500), IGF-2, and I-FABP. World J Hepatol 2026; 18(3): 112850
URL: https://www.wjgnet.com/1948-5182/full/v18/i3/112850.htm
DOI: https://dx.doi.org/10.4254/wjh.v18.i3.112850

Mohamed AA, Abdel-Hamid RM, Amin A, A Gawad EAH, Saed SM, Gaber DA, Ezz Al Arab M, El-Agawy W, AbuRahma MZA, Elosaily HH, Shaaban EE, Ismail SA, Sakr AA. Immunogenetic and molecular biomarkers in COVID-19 and hepatitis C virus infection: Evaluating the diagnostic potential of HLA (rs1131500), IGF-2, and I-FABP. World J Hepatol 2026; 18(3): 112850 [DOI: 10.4254/wjh.v18.i3.112850]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.